(Received December 3, 2012) Docosahexaenoic acid (DHA), a predominant of n-3 polyunsaturated fatty acids (n-3 PUFA), has numerous beneˆcial physiological eŠects, including neuroprotection and cardiovascular protection. Recently, a possible involvement of n-3 PUFA in pain control has gathered considerable attention because numerous studies have reported a regulatory role of n-3 PUFAs. However, the mechanisms underlying how DHA exerts antinociceptive eŠect remain unknown. Here, we performed elucidation of mechanisms underlying DHA-induced antinociception. DHA administration dosedependently exerted an antinociceptive eŠect. This eŠect was abolished by pretreated with the b-funaltrexamine (b-F-NA), a m-opioid receptor antagonist, and the nartrindole (NTI), a d-opioid receptor antagonist, but not by the norbinaltorphimine (nor-BNI), a k-opioid receptor antagonist. In the radioligand binding assay, DHA itself did not have the a‹nity for m-, d-and k-opioid receptor. Furthermore, the pretreatment of anti b-endorphin antiserum inhibited DHA-induced antinociception. The plasma levels of b-endorphin increased 30 min after DHA administration. The b-endorphin immunoreactivity in the brain increased at 30 min after DHA treatment. Expression of GPR40 protein was widely observed in the brain as well as the spinal cord. The intracerebroventricular but not intrathecal injection of DHA and GW9508, a GPR40/GPR120 agonist, signiˆcantly reduced formalin-induced pain behavior. The b-endorphin immunoreactivity in the brain increased at 10 and 20 min after intracerebroventricular injection of DHA and GW9508. Theseˆndings suggest that DHA-induced antinociception via b-endorphin release may be mediated through GPR40 signaling in the supraspinal area.

